Caffeine, Through Adenosine A3 Receptor-Mediated Actions, Suppresses Amyloid-β Protein Precursor Internalization and Amyloid-β Generation
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Intraneuronal accumulation and extracellular deposition of amyloid-β (Aβ) protein continues to be implicated in the pathogenesis of Alzheimer's disease (AD), be it familial in origin or sporadic in nature. Aβ is generated intracellularly following endocytosis of amyloid-β protein precursor (AβPP), and, consequently, factors that suppress AβPP internalization may decrease amyloidogenic processing of AβPP. Here we tested the hypothesis that caffeine decreases Aβ generation by suppressing AβPP internalization in primary cultured neurons. Caffeine concentration-dependently blocked low-density lipoprotein (LDL) cholesterol internalization and a specific adenosine A3 receptor (A3R) antagonist as well as siRNA knockdown of A3Rs mimicked the effects of caffeine on neuronal internalization of LDL cholesterol. Further implicating A3Rs were findings that a specific A3R agonist increased neuronal internalization of LDL cholesterol. In addition, caffeine as well as siRNA knockdown of A3Rs blocked the ability of LDL cholesterol to increase Aβ levels. Furthermore, caffeine blocked LDL cholesterol-induced decreases in AβPP protein levels in neuronal plasma membranes, increased surface expression of AβPP on neurons, and the A3R antagonist as well as siRNA knockdown of A3Rs mimicked the effects of caffeine on AβPP surface expression. Moreover, the A3R agonist decreased neuronal surface expression of AβPP. Our findings suggest that caffeine exerts protective effects against amyloidogenic processing of AβPP at least in part by suppressing A3R-mediated internalization of AβPP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624
Alzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424
Solomon, A., Kivipelto, M., Wolozin, B., Zhou, J., & Whitmer, R. A. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000231980 · Cited by 557 · cited 1×
“…processing of A PP thus leading to increased AD (cid:1) internalization may decrease amyloidogenic process-ingofA (cid:1) PPandthusmightdecreaseADpathogenesis (LDL) cholesterol, independent of APOE genotypes is a robust extrinsic factor that increases the risk of developing sporadic AD [10–14].”
Midlife Coffee and Tea Drinking and the Risk of Late-Life Dementia: A Population-Based CAIDE Study
Eskelinen, M. H., Ngandu, T., Tuomilehto, J., Soininen, H., & Kivipelto, M. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0920 · Cited by 428
Adenosine receptors and brain diseases: neuroprotection and neurodegeneration
Gomes, C. V., Kaster, M. P., Tomé, A. R., Agostinho, P. M., & Cunha, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.001 · Cited by 419 · cited 1×
“Importantly, activation of adenosine receptors (A1R and A2AR) has been implicated previously in the pathogenesis of AD [52–54], and blockage of A2AR with caffeine has been shown to suppress A generation [34, 38] and protect against A -induced neurotoxicity [55].”
Blood—Brain Barrier Permeability Precedes Senile Plaque Formation in an Alzheimer Disease Model
UJIIE, M., DICKSTEIN, D. L., CARLOW, D. A., & JEFFERIES, W. A. (2003) · Microcirculation · doi:10.1038/sj.mn.7800212 · Cited by 351
The neuroprotective effects of caffeine: A prospective population study (the Three City Study)
Ritchie, K., Carrière, I., de Mendonça, A., Portet, F., Dartigues, J. F., Rouaud, O., Barberger-Gateau, P., & Ancelin, M. L. (2007) · Neurology · doi:10.1212/01.wnl.0000266670.35219.0c · Cited by 347
Arendash, G. W., Mori, T., Cao, C., Mamcarz, M., Runfeldt, M., Dickson, A., Rezai-Zadeh, K., Tan, J., Citron, B. A., Lin, X., et al. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1087 · Cited by 308
Sannerud, R., Declerck, I., Peric, A., Raemaekers, T., Menendez, G., Zhou, L., Veerle, B., Coen, K., Munck, S., De Strooper, B., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100745108 · Cited by 286
Associations Between Serum Cholesterol Levels and Cerebral Amyloidosis
Reed, B., Villeneuve, S., Mack, W., DeCarli, C., Chui, H. C., & Jagust, W. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5390 · Cited by 267
Morel, E., Chamoun, Z., Lasiecka, Z. M., Chan, R. B., Williamson, R. L., Vetanovetz, C., Dall’Armi, C., Simoes, S., Point Du Jour, K. S., McCabe, B. D., et al. (2013) · Nature Communications · doi:10.1038/ncomms3250 · Cited by 222
Crystal Structure of an Active Form of BACE1, an Enzyme Responsible for Amyloid β Protein Production
Shimizu, H., Tosaki, A., Kaneko, K., Hisano, T., Sakurai, T., & Nukina, N. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.02185-07 · Cited by 205
Caffeine protects against MPTP‐induced blood‐brain barrier dysfunction in mouse striatum
Chen, X., Lan, X., Roche, I., Liu, R., & Geiger, J. D. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05697.x · Cited by 189 · cited 1×
“Samples were run with our iCycler IQTM Multicolor Real-Time PCR Detection System (Bio-Rad) that monitors fluorescence as a direct indication of PCR product [40].”
Self-citationCoffee Intake in Midlife and Risk of Dementia and its Neuropathologic Correlates
Gelber, R. P., Petrovitch, H., Masaki, K. H., Ross, G. W., & White, L. R. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101428 · Cited by 133
Caffeine Intake is Associated with a Lower Risk of Cognitive Decline: A Cohort Study from Portugal
Santos, C., Lunet, N., Azevedo, A., de Mendonça, A., Ritchie, K., & Barros, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091303 · Cited by 100
Brodeur, J., Thériault, C., Lessard-Beaudoin, M., Marcil, A., Dahan, S., & Lavoie, C. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-31 · Cited by 77 · cited 3×
“This basic biological effect might be of significance to the pathogenesis of AD because amyloidogenic processing of A PP occurs predominantly within endolysosomes after A PP is internalized, and because LDLRs interact with A PP and affect A PP trafficking [18–20].”
Cited by
Purinergic Signalling: Therapeutic Developments
Burnstock, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00661 · Cited by 398
Caffeine as a factor influencing the functioning of the human body-friend or foe?
Rodak, K., Kokot, I., & Kratz, E. M. (2021) · Nutrients · doi:10.3390/nu13093088 · Cited by 188
“[52] described a mechanism whereby caffeine protects against Aβ generation.”
BackgroundCoffee intake and decreased amyloid pathology in human brain
Kim, J. W., Byun, M. S., Yi, D., Lee, J. H., Jeon, S. Y., Jung, G., Lee, H. N., Sohn, B. K., Lee, J.-Y., Kim, Y. K., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0604-5 · Cited by 86
Akyuz, E., Arulsamy, A., Aslan, F. S., Sarisözen, B., Guney, B., Hekimoglu, A., Yilmaz, B. N., Retinasamy, T., & Shaikh, M. F. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04333-y · Cited by 69
“…a li za ti on o f t h e A β p r o t e i n p r ec u r s o r C a ff e i n e ca n i nh i b it a m y l o i dog e n i c p r o ce ss - i ng o f t h e A β p r o t e i n p r ec u r s o r v i a t h e A 3 R [ 305 ] , I n v it r o , i n v i vo A n i m a l m od e l o f 3x T g m ou s e i n AD S C H 58261 ( 0 .”
Metadata
- Authors
- Li, S., Geiger, N. H., Soliman, M. L., Hui, L., Geiger, J. D., & Chen, X.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2015-07-09
- Volume
- 47
- Issue
- 1
- Pages
- 73-83
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2213408344
- Cited by
- 35
- References
- 16
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.